Quick Facts: Sulcran

• Addresses: Symptoms associated with various types of arthritis.
• Supports: The temporary relief of discomfort and joint stiffness.
• Used for: Acute painful conditions like bursitis and tendonitis.

---

What Sulcran Treats: Main Uses and Benefits

Sulcran is a prescription medication utilized in the management of specific conditions where pain and inflammation are present. Its primary role is to provide relief for the symptoms associated with different forms of arthritis, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. For individuals with these conditions, Sulcran may support the temporary reduction of joint pain, swelling, and stiffness.

In addition to the management of chronic conditions, this medication is also employed to address acute, painful musculoskeletal conditions. This includes the management of bursitis (inflammation of a bursa) and tendonitis (inflammation of a tendon) in a general timeframe. The primary therapeutic goal is symptom relief, as the medication does not alter the underlying progression of the conditions it is used to treat. Consult a qualified healthcare professional to determine if Sulcran is an appropriate option for your specific clinical needs.

Who Can and Cannot Use Sulcran?

Eligibility for using Sulcran (Sucralfate) is defined by official regulatory labeling, outlining specific patient populations who are permitted, restricted, or prohibited from use.

Absolute Contraindications

Sulcran is contraindicated and must not be used by patients with a known hypersensitivity or allergy to the active ingredient, Sucralfate, or to any component of the formulation. For patients with impaired kidney function who are undergoing dialysis, use is also restricted due to the potential risk of aluminum accumulation.

Population Restrictions and Cautions

Use requires caution in patients with chronic renal failure because the aluminum component of Sulcran can build up in the body when kidney function is severely impaired. The medicine should be used with caution in patients with underlying conditions that increase the risk of bezoar formation, such as delayed gastric emptying or concurrent enteral tube feedings.

Age and Physiological Status

Safety and effectiveness have not been established in the pediatric population (under 18 years of age) according to U.S. regulatory guidelines. For older adults, caution is advised, often necessitating use at the lower end of the dosing range due to the increased frequency of decreased organ function. During pregnancy and lactation, Sulcran should be used only if clearly needed, as adequate human study data are not available to fully establish its safety status.

Sulcran Interactions with other medicines and products

The interaction profile for Sulcran (Sucralfate) is defined by its localized action in the digestive tract, primarily involving two categories of documented interaction patterns.

---

Pharmacokinetic Interactions (Reduced Systemic Exposure)

The main interaction pattern is a nonsystemic pharmacokinetic interaction where Sulcran physically binds to co-administered oral medications in the stomach, which consequently reduces their systemic absorption (bioavailability). This effect is documented for numerous substances, including antibiotics such as fluoroquinolones (e.g., ciprofloxacin, norfloxacin), antifungal agents like ketoconazole, cardiovascular agents such as digoxin and quinidine, and thyroid hormones like levothyroxine (L-thyroxine). To avoid this reduction in exposure, official regulatory documents mandate a timing rule: affected oral medications must be administered 2 hours before the dose of Sulcran. Antacids must be administered at least 30 minutes before or after Sulcran.

---

Pharmacodynamic Interactions (Additive Aluminum Load)

Sulcran is an aluminum salt, and its interaction profile includes pharmacodynamic considerations related to aluminum exposure. Co-administration with other aluminum-containing products may result in an additive increase in the total aluminum body burden. This restriction is especially relevant for patients with chronic renal failure or those on dialysis. Because these patients have an impaired ability to excrete absorbed aluminum, the regulatory labeling notes that combining Sulcran with other aluminum sources increases the risk of aluminum accumulation and subsequent toxicity.

Sulcran, which contains the active ingredient Sucralfate, exerts its unique action through a localized, dual-pronged mechanism focused entirely on the gastro-duodenal mucosa. The mechanism is driven by its pH-dependent chemistry, resulting in localized action.

Targeted Physico-chemical Barrier Formation

The primary mechanism relies on pH-dependent polymerization and physico-chemical binding to exposed proteins (like fibrinogen) in damaged tissue. In the presence of gastric acid (below pH 4), the drug transforms into a viscous, adhesive complex that preferentially adheres to ulcer craters. This creates an immediate, durable physical barrier that physically isolates the underlying cells from the action of HCl, pepsin, and bile salts.

Local Modulation of Cytoprotective Pathways

The physical presence of the drug at the lesion site also initiates biochemical modulation of local repair mechanisms. It indirectly stimulates the synthesis and release of prostaglandins ( PGE2), leading to enhanced mucosal blood flow and increased secretion of bicarbonate and mucus. Furthermore, it protects and concentrates growth factors (like EGF) where they are most needed, facilitating accelerated cellular regeneration and the re-establishment of mucosal structure.

Administration and Official Dosing Guidelines

Sulcran (Sulbactam and Durlobactam, co-packaged for intravenous use) is administered strictly as an intravenous (IV) infusion to adult patients (18 years of age and older). The standard dose is 1 gram (g) of sulbactam and 1 g of durlobactam.

Procedural Steps

The full dose must be administered by IV infusion over a period of 3 hours. The medication is supplied as a sterile powder and requires reconstitution and further dilution with 0.9% Sodium Chloride Injection, USP, using aseptic technique. Dilution must occur within 1 hour of the initial reconstitution. Prior to infusion, the final solution should be inspected for particulates and discoloration and must be allowed to reach ambient room temperature (over 15 to 30 minutes).

Dosage Adjustment Based on Renal Function

The dosing frequency must be adjusted based on the patient's estimated Creatinine Clearance (CLcr), as calculated by the Cockcroft-Gault equation. Healthcare professionals must monitor CLcr regularly and adjust the dose if renal function changes during therapy.

Estimated CLcr (mL/min)	Frequency (Sulbactam 1 g and Durlobactam 1 g)
≥ 130	Every 4 hours
45 to 129	Every 6 hours
30 to 44	Every 8 hours
15 to 29	Every 12 hours
< 15 (Initiating Therapy)	Every 12 hours for the first 3 doses, then every 24 hours

For patients undergoing hemodialysis, the dose should be administered after the dialysis session has concluded. The recommended duration of treatment is 7 to 14 days, guided by the patient's clinical status.

Research Evidence / Overview of Studies for Sulcran (Sucralfate)

---

Evidence for Healing Acute Duodenal Ulcers

Research examining Sulcran (sucralfate) for acute duodenal ulcers has primarily been conducted using Randomized Controlled Trials (RCTs). In these trials, researchers explored how the ulcer evolved during the study period over short-term intervals, typically spanning four to eight weeks. The main goal of these studies was to measure the rate of endoscopic healing, which involves visual confirmation of changes in ulcer size. Trials reported measurements of the ulcer healing endpoint, and findings helped contextualize how patients reported their experience. What remains uncertain is the need for more comparative evidence against current standard treatments.

---

Evidence for Preventing Ulcer Recurrence (Maintenance Use)

Following the healing of an acute duodenal ulcer, studies have explored the use of Sulcran as a long-term maintenance therapy. These controlled studies evaluated the potential of the medicine to maintain healing. The main outcome observed was the rate of ulcer recurrence, tracking whether a healed ulcer reopened during observation periods that sometimes lasted up to one year. Findings described patterns in some trials where the use of Sulcran was associated with a measurement of recurrence rate compared to a non-active comparator. Data for certain groups remain insufficient, and the evidence base provides limited insight into long-term outcomes for patients in certain complex clinical scenarios.

---

Evidence for Preventing Stress-Related Bleeding in Critical Care

Research has also examined Sulcran’s use in specific high-risk settings, such as Intensive Care Units (ICUs). These studies focused on critically ill adults who face a heightened risk of stress-related mucosal damage. The primary critical outcome measured was the frequency of clinically important gastrointestinal bleeding events. Trials described patterns where the use of the medicine was associated with observed changes in GI bleeding frequency in this critically ill population. However, evidence quality varies across studies regarding certain secondary outcomes, such as the potential impact on the occurrence of hospital-acquired pneumonia.

---

What Remains Uncertain About Sulcran's Research Base

The overall evidence landscape for Sulcran contributes to understanding symptom patterns, but it also contains several recognized limitations. Comparative evidence is lacking for many indications, particularly regarding head-to-head comparisons against standard treatments. Findings were mixed or inconsistent across studies for certain secondary outcomes. Furthermore, evidence quality varies across studies, and data for certain patient groups, such as those with specific comorbidities or varying levels of disease severity, remain limited.

Key Studies & References

1. Gastro-duodenal Protective Agents (Cytoprotective Agents) - StatPearls [Internet]
2. Guidelines for the Prevention and Management of Stress Ulceration in the ICU

Common questions about Sulcran (FAQ)

---

Q: Can Sulcran affect sleep patterns?

Official labeling documents note that sleep problems (insomnia) have been reported as a side effect. These are classified as a rare effect in official product information. Concerns about changes in sleep patterns may be discussed with a healthcare professional.

---

Q: How is Sulcran meant to be stored?

Official regulatory guidance states that Sulcran is to be stored at a controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The liquid suspension form of the medicine is specified in official instructions as needing to be protected from freezing to maintain its stability.

---

Q: What should be avoided when taking Sulcran?

Official labeling describes a known hypersensitivity or allergy to its active ingredient, Sucralfate, as a contraindication for use. The medicine can also reduce the absorption of other oral drugs, so co-administered oral medications should be separated by at least two hours. Use with caution is noted for patients with severe chronic kidney failure due to the aluminum content.

---

Q: How quickly does Sulcran start working?

Regulatory documents describe the mechanism of action as an immediate physical and chemical process. Upon contact with stomach acid, the drug transforms into a viscous, adhesive complex that quickly forms a physical protective barrier over damaged tissue.

---

Q: How long do the reported effects of Sulcran usually last?

Studies indicate that the protective action of Sulcran is sustained because the adhesive complex has a strong affinity for damaged tissue. The recommended dosing frequency described in regulatory documents is intended to maintain the protective barrier.

---

Q: Can Sulcran be taken with over-the-counter pain relievers?

The official product information states that Sulcran can reduce the absorption of many co-administered oral medications. This means a separation time is necessary for certain non-prescription pain relievers. Guidance from a healthcare professional may be needed regarding the required two-hour separation time for specific over-the-counter products.

---

Q: Are there any common foods or drinks that interact with Sulcran?

Official documents state that the medicine is generally most effective when taken on an empty stomach. While the label does not list specific common foods that interact, its effectiveness can be affected because its unique action requires the presence of stomach acid. It is noted, however, that the medicine can interfere with enteral (tube) feedings.

---

Q: Is it common to feel tired when starting Sulcran?

The official adverse reaction lists do not specifically include 'tiredness' or 'fatigue' as common side effects. However, the regulatory documents do list dizziness and drowsiness as reported effects on the central nervous system.

---

Q: What should be done if a potential side effect is noticed?

The official patient information includes documentation that suspected side effects may be reported to a healthcare provider. Serious health events, such as signs of a severe allergic reaction or an intestinal blockage, are documented as requiring immediate medical attention.

---

Q: Does Sulcran have any known interactions with herbal supplements?

The official product label instructs patients to inform their healthcare provider about all supplements and other non-prescription products they are using. This is because Sulcran has the potential to interact with other orally administered products by reducing their absorption.

---

Q: What if I forget to take my Sulcran at the usual time?

The official patient information describes a process where a missed dose is to be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is to be skipped. The documentation specifies not taking extra medicine to account for a missed dose.

---

Q: Why are there different strengths of Sulcran available?

The medicine is available in two forms: tablets and an oral suspension. Official documents note that the choice of form and dosage strength is often guided by whether the medicine is being used for the treatment of acute ulcers or for long-term maintenance therapy.

---

Q: How should unused Sulcran be disposed of?

Regulatory guidelines describe using a drug take-back program or specialized mail-back envelope as a suitable option for disposing of unused Sulcran. If no program is available, the medicine may be mixed with an undesirable substance (like dirt) and placed in a sealed container before being thrown in the household trash. Official guidance indicates that the medicine is not to be flushed down a toilet or sink.

---

Q: What does the official patient information leaflet say about overdose?

The patient information provided by regulatory authorities includes documentation that seeking emergency medical attention or contacting a Poison Help line is the recommended course of action if an overdose of Sulcran is suspected.

---

Q: Are there specific instructions for stopping Sulcran?

The recommended duration of treatment for acute ulcers is typically 4 to 8 weeks, with the continuation of treatment dependent on confirmation of healing. Decisions regarding starting or stopping the medicine are typically managed by a healthcare professional.

The official regulatory documents specify precise conditions for storing and disposing of Sulcran (Sucralfate) to maintain its stability.

Storage Requirements

Condition	Requirement	Constraint
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)	Excursions permitted 15 C to 30 C
Handling	Must be stored away from excess heat and moisture.	AVOID FREEZING the oral suspension.
Container	Keep the product in its original container, tightly closed.	Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Sulcran must be handled as pharmaceutical waste. Disposal must be performed according to the specific local regulations or a community drug take-back program. It is prohibited to dispose of this medication by flushing it down a toilet or pouring it down a sink.